利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.024 秒)

    BLOOD MONITORING SYSTEM FOR DETECTING OCCULT HEMORRHAGES
    2.
    发明申请
    BLOOD MONITORING SYSTEM FOR DETECTING OCCULT HEMORRHAGES 有权

    公开(公告)号：US20220193320A1

    公开(公告)日：2022-06-23

    申请号：US17132710

    申请日：2020-12-23

    申请人： Fresenius Medical Care Holdings, Inc. ,  Fresenius Medical Care Deutschland GmbH

    发明人： Sabrina Rogg ,  Peter Kotanko

    IPC分类号： A61M1/36 ,  A61M1/16

    摘要： A method for detecting occult hemorrhages is provided. The method comprises: obtaining, by a medical system comprising a blood monitoring system, a first hematocrit concentration prior to infusing a saline solution into a bloodstream of the patient; infusing, by the medical system, the saline solution into the bloodstream of the patient; obtaining, by the medical system, a second hematocrit concentration after infusing the saline solution into the bloodstream; determining, by the medical system, a first absolute blood volume based on the first hematocrit concentration and the second hematocrit concentration; generating, by the medical system, a notification indicating a potential occult hemorrhage based on the first absolute blood volume and a pre-defined absolute blood volume threshold; and providing, by the medical system, the notification indicating the potential occult hemorrhage.

    TECHNIQUES FOR INCREASING RED BLOOD CELL COUNT
    7.
    发明公开
    TECHNIQUES FOR INCREASING RED BLOOD CELL COUNT 审中-公开

    公开(公告)号：US20230405201A1

    公开(公告)日：2023-12-21

    申请号：US18032931

    申请日：2021-11-12

    申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. ,  FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

    发明人： Peter Kotanko ,  Nadja Grobe ,  Christoph Zaba ,  David Joerg ,  Frank Gebauer

    IPC分类号： A61M1/34

    CPC分类号： A61M1/3486 ,  A61M2202/0498

    摘要： The described technology may include treatment processes to increase the red blood cell (RBC) population of individuals, particularly chronic kidney disease (CKD) patients with renal anemia, by reducing an amount of Piezo1 chemical agonists in the blood of patients. In one embodiment, a method of treating a patient with renal anemia may include increasing RBC lifespan of an RBC population of the patient via reduction of a Piezo1 channel activation duration of at least a portion of the RBC population by reducing an amount of a target uremic compound in the blood of the patient, the target uremic compound having a form that prolongs the Piezo1 channel activation duration, wherein the amount of the target uremic compound may be reduced via selectively removing at least a portion of the target uremic compound from the blood of the patient. Other embodiments are described.

    PARABIOTIC DIALYSIS SYSTEMS AND TECHNIQUES
    8.
    发明申请
    PARABIOTIC DIALYSIS SYSTEMS AND TECHNIQUES 有权

    公开(公告)号：US20220008633A1

    公开(公告)日：2022-01-13

    申请号：US17352656

    申请日：2021-06-21

    申请人： Fresenius Medical Care Deutschland GmbH ,  Fresenius Medical Care Holdings, Inc.

    发明人： Stefan Weiss ,  Peter Kotanko ,  Roland Sander

    IPC分类号： A61M1/16

    摘要： The present teachings generally include parabiotic dialysis systems and techniques. For example, the present disclosure includes parabiotic liver dialysis, e.g., for use in settings with limited resources. To this end, a parabiotic liver dialysis system may include a device having a semipermeable membrane with an average pore size that allows for the passage of albumin therethrough. In such a system, a first extracorporeal circuit may connect the device to the vascular system of a first animal (e.g., a liver patient), and a second extracorporeal circuit may connect the device to the vascular system of a second animal (e.g., a human with normal liver function), where the exchange of albumin therebetween is facilitated through the device. The present disclosure also includes various safety measures for parabiotic dialysis systems and techniques, such as biometric verification systems and techniques.

    Blood monitoring system for detecting occult hemorrhages
    9.
    发明授权
    Blood monitoring system for detecting occult hemorrhages 有权

    公开(公告)号：US12090257B2

    公开(公告)日：2024-09-17

    申请号：US17132710

    申请日：2020-12-23

    申请人： Fresenius Medical Care Holdings, Inc. ,  Fresenius Medical Care Deutschland GmbH

    发明人： Sabrina Casper ,  Peter Kotanko

    IPC分类号： A61M1/16 ,  A61M1/36

    CPC分类号： A61M1/1603 ,  A61M1/3609 ,  A61M2205/18 ,  A61M2230/207

    摘要： A method for detecting occult hemorrhages is provided. The method includes obtaining a first hematocrit concentration prior to infusing a saline solution into a bloodstream of a patient. The method further includes infusing the saline solution into the bloodstream of the patient and obtaining a second hematocrit concentration after infusing the saline solution into the bloodstream. The method also includes determining a first absolute blood volume based on the first hematocrit concentration and the second hematocrit concentration. In addition, the method includes generating a notification indicating a potential occult hemorrhage based on the first absolute blood volume and a pre-defined absolute blood volume threshold, and providing the notification indicating the potential occult hemorrhage.

    Medical Functional Device for Hemodialysis, Balancing Device and Method
    10.
    发明公开
    Medical Functional Device for Hemodialysis, Balancing Device and Method 审中-公开

    公开(公告)号：US20240216596A1

    公开(公告)日：2024-07-04

    申请号：US18086899

    申请日：2022-12-22

    申请人： Fresenius Medical Care Deutschland GmbH ,  Fresenius Medical Care Holdings, Inc.

    发明人： Peter Kotanko ,  Dejan Nikolic ,  Alexander Heide

    IPC分类号： A61M1/36 ,  A61M39/10

    CPC分类号： A61M1/3621 ,  A61M39/10 ,  A61M2205/3331

    摘要： The present disclosure relates to a medical functional device or arrangement of components having a first blood circuit for extracorporally withdrawing and reintroducing blood from and to a patient (P), and a second blood circuit for extracorporally withdrawing and reintroducing blood from and to a person (D), wherein both the first blood circuit and the second blood circuit each comprise an arterial line and a venous line. In this, the medical functional device, or the arrangement, comprises at least one connecting device for establishing a fluid communication between the arterial line of the first blood circuit for the patient (P) with the venous line (73) of the second blood circuit for the person (D) and for establishing a fluid communication between the arterial line of the second blood circuit for the person (D) with the venous line of the first blood circuit for the patient (P).